A Diabetes Pill That Works Like an Injection? The Phase 3 Results Are In
A large Phase 3 trial suggests a once-daily pill could soon offer the same blood sugar control as a weekly injection — no needles required.
Most people assume that if a drug works, it probably comes in a pill. With GLP-1 medications, that hasn't been the case — until now. A major clinical trial just reported that an oral GLP-1 drug matched the blood sugar-lowering power of an injected competitor, and the results are turning heads in diabetes medicine.
What Is a GLP-1 Drug, Anyway?
GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut naturally releases after you eat, and it helps your body manage blood sugar by telling the pancreas to release insulin and signaling the brain that you're full.
GLP-1 receptor agonists are drugs that mimic this hormone. You've likely heard of them — semaglutide, sold as Ozempic and Wegovy, is the most well-known. These drugs have become household names for both type 2 diabetes management and weight loss. But until recently, the most effective versions had to be injected.
What the Phase 3 Trial Found
The trial in question tested orforglipron, an oral GLP-1 pill developed by Eli Lilly, against injectable dulaglutide (brand name Trulicity) in adults with type 2 diabetes. Results were published in the New England Journal of Medicine.
The trial enrolled more than 900 participants and ran for about 40 weeks. Researchers found that orforglipron lowered HbA1c — a key measure of long-term blood sugar control — by amounts comparable to the injected drug. Participants taking the pill also saw meaningful reductions in body weight.
This is notable because getting a GLP-1 drug to work effectively in pill form is genuinely difficult. The molecule is fragile and typically breaks down in the digestive system before it can be absorbed. Orforglipron uses a different molecular structure that doesn't have that problem, which is what makes this result significant.
Important Caveats to Keep in Mind
A Phase 3 trial is a serious, large-scale study — but it's one step in a longer process. The drug has not yet been approved by the FDA, and this trial was funded by Eli Lilly, the manufacturer, which is standard in pharmaceutical research but worth noting.
The study focused on blood sugar control and weight over roughly 40 weeks. Long-term safety data — the kind that comes from years of real-world use — is still being gathered. And as with all GLP-1 drugs, side effects in the trial included nausea, vomiting, and diarrhea, particularly in the early weeks of treatment.
This was also a comparison against dulaglutide, not against semaglutide (Ozempic/Wegovy), which is currently considered one of the more potent GLP-1 options. How an oral pill would compare to the most powerful injectables head-to-head remains an open question.
Why This Matters for People With Diabetes
Needle aversion is real, and it's one of the reasons some people with type 2 diabetes delay or avoid medication that could genuinely help them. An effective once-daily pill could remove that barrier entirely.
There is already one FDA-approved oral semaglutide pill — Rybelsus — but it requires a very specific dosing routine (taken on an empty stomach with a small amount of water, followed by 30 minutes without food or other medications) and has generally shown more modest effects than the injectable versions. Orforglipron, if approved, could offer a simpler option with stronger results.
For patients, more options mean more flexibility. A conversation with your doctor can help determine what approach makes the most sense for your individual situation.
Where Things Stand Right Now
Orforglipron is not yet available. Eli Lilly has announced it plans to submit the drug for FDA approval, and additional trial data — including results focused on weight loss in people without diabetes — have also been reported. Regulatory review takes time, and approval is not guaranteed.
Other pharmaceutical companies are also working on oral GLP-1 options, so this space is moving quickly. It's worth watching.
The Bottom Line
A Phase 3 clinical trial published in the New England Journal of Medicine found that an oral GLP-1 pill called orforglipron matched the blood sugar-lowering effect of an injected diabetes drug in adults with type 2 diabetes. The drug isn't approved yet, but if it clears FDA review, it could offer a needle-free alternative for people who need this class of medication. Talk with your doctor about whether a GLP-1 treatment — pill or injection — might be right for you.
